Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y, Tanaka Y, Matsumura T, Kadoh Y, Miyoshi H, Hongu M, Takedomi K, Kotera J, Sasaki T, Taniguchi H, Watanabe Y, Takakuwa M, Kojima K, Baba N, Nakamura I, Kawanishi E. Koizumi Y, et al. Among authors: watanabe y. Bioorg Med Chem. 2019 Aug 1;27(15):3440-3450. doi: 10.1016/j.bmc.2019.06.021. Epub 2019 Jun 19. Bioorg Med Chem. 2019. PMID: 31235264
Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y, Asai H, Ishii T, Kiuchi S, Okamoto M, Taniguchi H, Nagasaki M, Saito A. Watanabe Y, et al. J Pharmacol Sci. 2008 Jan;106(1):121-7. doi: 10.1254/jphs.fp0071400. Epub 2008 Jan 11. J Pharmacol Sci. 2008. PMID: 18187929 Free article.
Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y, Miyoshi H, Matsumura T, Tanaka Y, Hongu M, Kimura M, Takedomi K, Omori K, Kotera J, Sasaki T, Kobayashi T, Taniguchi H, Watanabe Y, Kojima K, Sakamoto T, Himiyama T, Kawanishi E. Kadoh Y, et al. Among authors: watanabe y. Chem Pharm Bull (Tokyo). 2018;66(3):243-250. doi: 10.1248/cpb.c17-00783. Chem Pharm Bull (Tokyo). 2018. PMID: 29491258 Free article.
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M. Kadowaki T, et al. Among authors: watanabe y. Diabetes Obes Metab. 2017 Jun;19(6):874-882. doi: 10.1111/dom.12898. Epub 2017 Mar 31. Diabetes Obes Metab. 2017. PMID: 28177187 Free PMC article. Clinical Trial.
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
Harashima SI, Inagaki N, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, Watanabe Y. Harashima SI, et al. Among authors: watanabe y. Diabetes Obes Metab. 2018 Jul;20(7):1770-1775. doi: 10.1111/dom.13267. Epub 2018 Mar 24. Diabetes Obes Metab. 2018. PMID: 29473709 Free PMC article. Clinical Trial.
12,091 results
You have reached the last available page of results. Please see the User Guide for more information.